Replies to post #243322 on Biotech Values

[jbog]

Abbvie's Hep C franchise continues the slow bleed. Eu had a 18% decline while U.S. stayed stagnant.

Doesn't seem like a post covid pop is in the works.

[DewDiligence]

ENTA’s PR on EDP-235 phase-1/1b data:

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-announces-positive-data-phase-1-clinical

Based on these positive safety and PK results, ENTA is advancing the 200mg qD and 400mg qD doses (without ritonavir boosting) to phase-2, which is expected to start in 4Q22.